ID   IMS-BC1
AC   CVCL_A7NE
DR   Wikidata; Q107115447
RX   PubMed=9650450;
RX   PubMed=10071072;
CC   Population: Japanese.
CC   Doubling time: 48 hours (PubMed=9650450).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9650450; PubMed=10071072).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 19-12-24; Version: 5
//
RX   PubMed=9650450; DOI=10.1016/s0925-5710(98)00007-3;
RA   Nagamura F., Nagamura-Inoue T., Tojo A., Minamihisamatsu M.,
RA   Tanabe T., Zaike Y., Tani K., Saisho H., Asano S.;
RT   "Establishment of novel cell lines derived from two patients with
RT   chronic myelogenous leukemia in blast crisis; IMS-BC1 and IMS-BC2
RT   which exhibit markedly different sensitivity to apoptosis.";
RL   Int. J. Hematol. 67:283-294(1998).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//